Morphine
Reference opioid agonist and primary active metabolite of heroin and codeine. Undergoes hepatic glucuronidation to active M6G (more potent, longer-acting) and inactive M3G. Terminal half-life ~2-3 hours for immediate release.
Projected serum levels — 10 mg, as needed (shown daily)
Maintenance schedule: 10 mg as needed (shown daily) (oral).
Modeled steady state after ~1 days: peak ≈ 1.9 mg, trough ≈ 0.004 mg body load. Population-based estimate over 15 days for a 10 mg dose at a 70 kg reference body mass — the interactive app scales curves to your doses, timing, and body mass.
Key facts
- Category
- Opioid
- Route modeled
- Oral
- Model confidence
- inferred
- Half-life
- 2.5 h
- Common dose
- 10 mg
- Reference dose range
- 2–90 mg (single dose)
- Suggested cadence
- as needed (shown daily)
- Validated against
- 30 mg oral — Cmax 0.050 mg/L at 1 h
Documented interactions
-
danger
1,4-BDO (1,4-Butanediol) + Morphine
1,4-BDO converts to GHB. Stacked with opioid respiratory depression, often fatal.
-
danger
7-Hydroxymitragynine (7-OH) + Morphine
7-Hydroxymitragynine (7-OH) and Morphine both push the delta opioid, kappa opioid, and mu opioid in the same direction.
-
danger
CBD (Cannabidiol) + Morphine
CBD (Cannabidiol) reversible_inhibitor of UGT2B7 predicted to change Morphine AUC by ~2.47x
-
danger
Cocaine + Morphine
Speedball combination: stimulant masks opioid sedation, leading to accidental overdose. Extreme cardiac strain.
-
danger
Codeine + Morphine
Combining opioids causes additive respiratory depression. Codeine is metabolized to morphine.
-
danger
Ethanol (Alcohol) + Morphine
Alcohol potentiates opioid respiratory depression.
Serum checks 52 modeled interaction pairings for morphine across your whole stack — absorption conflicts, enzyme inhibition, and nutrient depletion included.
Research behind this entry
-
Clinical Pharmacokinetics of Morphine
Comprehensive review of morphine pharmacokinetics including oral bioavailability of 20-30%, hepatic first-pass metabolism, glucuronidation to M3G and active M6G, and a terminal half-life of 2-3 hours.
-
Morphine in Postoperative Patients: Pharmacokinetics and Pharmacodynamics of Metabolites
Found morphine-6-glucuronide was 7.8 times more potent than morphine but with a delayed peak effect of 4.25 h compared to 0.33 h for morphine in postoperative patients.
-
A Review of Morphine and Morphine-6-Glucuronide Pharmacokinetic-Pharmacodynamic Relationships in Experimental and Clinical Pain
Reviewed population PK-PD models for morphine analgesia, covering drug disposition, active M6G metabolite pharmacology, and clinical variability in pain response.
-
Effect of Opioid vs Nonopioid Medications on Pain-Related Function in Patients With Chronic Back Pain or Hip or Knee Osteoarthritis Pain: The SPACE Randomized Clinical Trial
12-month RCT of 240 veterans found opioids (including sustained-release morphine) were NOT superior to non-opioid therapy for pain-related function in chronic back/hip/knee pain; pain intensity was actually worse in the…
5 published studies referenced in the app, each with a plain-language summary.